Terms: = Prostate cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12 AND Treatment
24 results:
1. Reirradiation salvage radiotherapy for recurrent prostate cancer after primary low-dose brachytherapy.
Muñoz Muñoz Ó; Gomis Sellés E; Delgado León BD; Mateos Perez JC; Baeza Trujillo M; Perucha Ortega M; López Guerra JL; Cabrera Roldán P
Clin Transl Oncol; 2024 Apr; 26(4):872-879. PubMed ID: 37672205
[TBL] [Abstract] [Full Text] [Related]
2. Supported progressive resistance exercise training to counter the adverse side effects of robot-assisted radical prostatectomy: a randomised controlled trial.
Ashton RE; Aning JJ; Tew GA; Robson WA; Saxton JM
Support Care Cancer; 2021 Aug; 29(8):4595-4605. PubMed ID: 33483790
[TBL] [Abstract] [Full Text] [Related]
3. Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
Labrecque MP; Brown LG; Coleman IM; Nguyen HM; Lin DW; Corey E; Nelson PS; Morrissey C
PLoS One; 2021; 16(1):e0245602. PubMed ID: 33471819
[TBL] [Abstract] [Full Text] [Related]
4. Targeting ret Kinase in Neuroendocrine prostate cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract] [Full Text] [Related]
5. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Katoh M
Int J Oncol; 2017 Nov; 51(5):1357-1369. PubMed ID: 29048660
[TBL] [Abstract] [Full Text] [Related]
6. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.
Reeser JW; Martin D; Miya J; Kautto EA; Lyon E; Zhu E; Wing MR; Smith A; Reeder M; Samorodnitsky E; Parks H; Naik KR; Gozgit J; Nowacki N; Davies KD; Varella-Garcia M; Yu L; Freud AG; Coleman J; Aisner DL; Roychowdhury S
J Mol Diagn; 2017 Sep; 19(5):682-696. PubMed ID: 28802831
[TBL] [Abstract] [Full Text] [Related]
7. Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis.
Yunfeng G; Weiyang H; Xueyang H; Yilong H; Xin G
Medicine (Baltimore); 2017 Jul; 96(27):e7368. PubMed ID: 28682886
[TBL] [Abstract] [Full Text] [Related]
8. Detection of Gene Rearrangements in Circulating Tumor Cells: Examples of ALK-, ROS1-, ret-Rearrangements in Non-Small-Cell Lung cancer and ERG-Rearrangements in prostate cancer.
Catelain C; Pailler E; Oulhen M; Faugeroux V; Pommier AL; Farace F
Adv Exp Med Biol; 2017; 994():169-179. PubMed ID: 28560674
[TBL] [Abstract] [Full Text] [Related]
9. [Cabozantinib: Mechanism of action, efficacy and indications].
Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S
Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875
[TBL] [Abstract] [Full Text] [Related]
10. Image Guided Radiation Therapy (IGRT) Practice Patterns and IGRT's Impact on Workflow and treatment Planning: Results From a National Survey of American Society for Radiation Oncology Members.
Nabavizadeh N; Elliott DA; Chen Y; Kusano AS; Mitin T; Thomas CR; Holland JM
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):850-7. PubMed ID: 26972658
[TBL] [Abstract] [Full Text] [Related]
11. Cabozantinib in Thyroid cancer.
Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A
Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149
[TBL] [Abstract] [Full Text] [Related]
12. DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
Huber RM; Lucas JM; Gomez-Sarosi LA; Coleman I; Zhao S; Coleman R; Nelson PS
Oncotarget; 2015 Feb; 6(4):2134-47. PubMed ID: 25575823
[TBL] [Abstract] [Full Text] [Related]
13. Cutaneous adverse effects associated with the tyrosine-kinase inhibitor cabozantinib.
Zuo RC; Apolo AB; DiGiovanna JJ; Parnes HL; Keen CM; Nanda S; Dahut WL; Cowen EW
JAMA Dermatol; 2015 Feb; 151(2):170-7. PubMed ID: 25427282
[TBL] [Abstract] [Full Text] [Related]
14. Cabozantinib: a MET, ret, and VEGFR2 tyrosine kinase inhibitor.
Grüllich C
Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794
[TBL] [Abstract] [Full Text] [Related]
15. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets.
Drake JM; Graham NA; Lee JK; Stoyanova T; Faltermeier CM; Sud S; Titz B; Huang J; Pienta KJ; Graeber TG; Witte ON
Proc Natl Acad Sci U S A; 2013 Dec; 110(49):E4762-9. PubMed ID: 24248375
[TBL] [Abstract] [Full Text] [Related]
16. Endoneurial macrophages induce perineural invasion of pancreatic cancer cells by secretion of GDNF and activation of ret tyrosine kinase receptor.
Cavel O; Shomron O; Shabtay A; Vital J; Trejo-Leider L; Weizman N; Krelin Y; Fong Y; Wong RJ; Amit M; Gil Z
Cancer Res; 2012 Nov; 72(22):5733-43. PubMed ID: 22971345
[TBL] [Abstract] [Full Text] [Related]
17. Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Keizman D; Maimon N; Gottfried M
Am J Clin Oncol; 2014 Jun; 37(3):289-96. PubMed ID: 22772426
[TBL] [Abstract] [Full Text] [Related]
18. Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Guérin O; Etienne-Grimaldi MC; Monteverde M; Sudaka A; Brunstein MC; Formento P; Lattanzio L; Maffi M; Tonissi F; Ortholan C; Pagès G; Fischel JL; Lo Nigro C; Merlano M; Milano G
Urol Oncol; 2013 Nov; 31(8):1567-75. PubMed ID: 22608542
[TBL] [Abstract] [Full Text] [Related]
19. Targeting surface nucleolin with multivalent HB-19 and related Nucant pseudopeptides results in distinct inhibitory mechanisms depending on the malignant tumor cell type.
Krust B; El Khoury D; Nondier I; Soundaramourty C; Hovanessian AG
BMC Cancer; 2011 Aug; 11():333. PubMed ID: 21812966
[TBL] [Abstract] [Full Text] [Related]
20. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
[Next]
